Surrozen, Inc. has announced a significant move to bolster its financial position by entering into an underwriting agreement for a stock offering. The company plans to sell 1,894,540 shares of its common stock at an offering price of $31.67 per share, aiming to raise approximately $60 million. This strategic decision is crucial for Surrozen as it continues to develop its operations in the competitive biological products sector.

The offering, which is expected to close on November 16, 2026, is part of Surrozen's ongoing efforts to secure funding necessary for its growth and operational needs. The agreement involves well-known underwriters, including Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and Cantor Fitzgerald & Co. This collaboration highlights the confidence these financial institutions have in Surrozen's business model and future prospects.

Background

Surrozen, Inc., incorporated in Delaware, operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company trades under the ticker symbol SRZN on the Nasdaq exchange. Recently, Surrozen has been active in the market, with several filings indicating ongoing developments and strategic maneuvers aimed at enhancing its market position.

What the Filing Says

According to the recent SEC filing, "On November 13, 2026, Surrozen, Inc. entered into an underwriting agreement... relating to the issuance and sale of 1,894,540 shares... at an offering price of $31.67 per share." The filing further states that the gross proceeds from the offering are expected to be approximately $60 million before deducting underwriting discounts and commissions.

Impact

This offering may significantly impact Surrozen's financial health, providing the necessary capital to support its ongoing research and development efforts. Additionally, it could influence investor sentiment within the biological products industry, prompting competitors to reassess their funding strategies and market approaches in light of Surrozen's expansion.

What's Next

The offering is set to close on November 16, 2026, pending the satisfaction of customary closing conditions. Following this, further updates regarding the use of the raised capital and any additional strategic initiatives are anticipated.